Published in Arthritis Res Ther on March 01, 2005
TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol (2007) 1.85
Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc (2009) 1.38
The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther (2008) 1.33
TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm (2010) 1.20
Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc (2012) 1.18
Drug-induced glomerular disease: immune-mediated injury. Clin J Am Soc Nephrol (2015) 1.01
Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus(). Open Rheumatol J (2012) 0.96
Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol (2015) 0.95
The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol (2013) 0.93
The role of cytokine in the lupus nephritis. J Biomed Biotechnol (2011) 0.90
Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. J Dtsch Dermatol Ges (2012) 0.89
Mechanisms of tumor necrosis factor α antagonist-induced lupus in a murine model. Arthritis Rheumatol (2015) 0.84
New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review. ScientificWorldJournal (2014) 0.83
The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients. Clin Exp Med (2008) 0.83
Efficacy and safety of adalimumab in Crohn's disease. Therap Adv Gastroenterol (2008) 0.82
Chilblain lupus induced by TNF-α antagonists: a case report and literature review. Clin Rheumatol (2011) 0.82
Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab. Arthritis Res Ther (2009) 0.80
Tumour necrosis factor inhibitor-related lupus: safety of switching agents. Clin Rheumatol (2010) 0.80
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80
4G/5G plasminogen activator inhibitor-1 and -308 A/G tumor necrosis factor-α promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis. Clin Exp Med (2012) 0.79
Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol (2013) 0.79
Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis. BMJ Case Rep (2014) 0.79
Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis. Postepy Dermatol Alergol (2015) 0.79
Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res Ther (2011) 0.78
Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis. Rheumatol Int (2008) 0.77
Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol (2013) 0.77
Acrylamine-induced autoimmune phenomena. Clin Rheumatol (2010) 0.77
The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag (2007) 0.76
The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis. Semin Nephrol (2015) 0.76
A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept. Rheumatol Int (2012) 0.75
Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α. Int Arch Med (2012) 0.75
Response to the comment by Park et al. entitled "is there is a link between Escherichia coli septicaemia and the onset of systemic lupus erythematosus?". Rheumatol Int (2013) 0.75
[Systemic lupus erythematosus induced by isoniazid: a rare complication to fear]. Pan Afr Med J (2015) 0.75
Cardiac Tamponade as a Presenting Manifestation of Infliximab-Induced Lupus in Patient Treated for Crohn's Disease. ACG Case Rep J (2017) 0.75
Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome. Case Rep Rheumatol (2014) 0.75
TNFα inhibitor induced lupus-like syndrome (TAILS) in a patient with IBD. Curr Health Sci J (2014) 0.75
Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE). Pharmaceuticals (Basel) (2010) 0.75
Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results. Rheumatol Int (2006) 0.75
Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open (2017) 0.75
Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. J Immunol Res (2016) 0.75
Adalimumab-induced lupus serositis. BMJ Case Rep (2015) 0.75
The Changing Landscape of Renal Inflammation. Trends Mol Med (2016) 0.75
Infliximab-induced autoantibodies: a multicenter study. Clin Rheumatol (2015) 0.75
Lupus attributable to anti-TNF therapy and revealed by interstitial granulomatous dermatitis. Rheumatol Int (2011) 0.75
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 43.47
Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 4.68
Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum (2000) 3.10
Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol (2003) 1.68
In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol (2001) 1.59
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis (2003) 1.44
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum (2003) 1.41
Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis (2004) 1.38
Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol (2003) 1.32
Antithrombotic activity of TNF-alpha. J Clin Invest (2003) 1.25
Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis (2002) 1.10
Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis (1999) 1.06
Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum (2003) 1.02
Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology (2003) 1.01
Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med (2004) 0.99
[Treatment of inflammatory diseases: safety of long-term use of infliximab]. Presse Med (2001) 0.82
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med (2002) 7.52
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 3.64
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum (2005) 3.44
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A (2006) 3.11
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum (2010) 2.68
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum (2004) 2.44
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum (2008) 2.41
Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med (2014) 2.36
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol (2005) 2.35
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis (2009) 2.20
Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood (2002) 2.12
Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort. Arthritis Care Res (Hoboken) (2013) 2.09
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis (2012) 2.06
Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum (2003) 2.03
Efficacy of anti-TNF in patients with spondyloarthritis in absence of any imaging sign. Joint Bone Spine (2012) 1.98
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther (2006) 1.90
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther (2009) 1.87
2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine (2012) 1.85
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis (2007) 1.83
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum (2011) 1.83
Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet (2013) 1.79
Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine (2006) 1.77
A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: the 'FLARE' instrument. Ann Rheum Dis (2011) 1.77
Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood (2012) 1.73
B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther (2006) 1.72
RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol (2002) 1.72
Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum (2007) 1.67
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 1.65
Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther (2009) 1.61
Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol (2011) 1.60
The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort. J Rheumatol (2009) 1.59
Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum (2011) 1.56
Sensitivity and specificity of ultrasonography in early diagnosis of metatarsal bone stress fractures: a pilot study of 37 patients. J Rheumatol (2009) 1.56
Defensin is suppressed by tick salivary gland extract during the in vitro interaction of resident skin cells with Borrelia burgdorferi. J Invest Dermatol (2009) 1.56
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54
2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine (2014) 1.54
Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis. J Rheumatol (2006) 1.53
Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol (2012) 1.52
Bacteremia in patients receiving TNF-alpha antagonists--a prospective multicenter study. J Infect (2013) 1.52
Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) (2009) 1.51
Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther (2010) 1.49
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis (2006) 1.47
Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol (2004) 1.46
Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion. Joint Bone Spine (2010) 1.46
Efficacy of anakinra in a case of refractory Still disease. J Clin Rheumatol (2008) 1.46
Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther (2006) 1.45
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Who are the patients with early arthritis with worse than death scores on the EQ-5D? Results from the ESPOIR cohort. Rheumatology (Oxford) (2012) 1.44
Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. Arthritis Res Ther (2012) 1.44
The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine (2007) 1.44
Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol (2013) 1.42
Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry. Clin Exp Rheumatol (2012) 1.42
Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum (2012) 1.41
Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics (2011) 1.41
Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol (2013) 1.41
The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine (2011) 1.41
Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum (2002) 1.41
Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. Arthritis Rheum (2007) 1.40
Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) (2014) 1.39
Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. J Rheumatol (2013) 1.39
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis (2006) 1.38
Ultrasound features of nonstructural lesions of the proximal and distal interphalangeal joints of the hands in patients with finger osteoarthritis. Joint Bone Spine (2010) 1.38
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis (2011) 1.37
In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum (2003) 1.36
Bruton's tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes. J Immunol (2009) 1.30
CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome. J Autoimmun (2005) 1.28
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford) (2013) 1.28
Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J Rheumatol (2011) 1.27
Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther (2006) 1.27